Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibecototamab Combined With Putilimab in EGFR-positive Refractory Advanced Biliary Tract Malignancies
NCT07472933Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and putilimab in biliary tract cancer (BTC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Overall Response Rate up to 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinputilimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07472933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472933.